Advice

in the absence of a submission from the holder of the marketing authorisation

afatinib (Giotrif®) is not recommended for use within NHS Scotland.

Indication under review: As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice110KB (PDF)

Download

Medicine details

Medicine name:
afatinib (Giotrif)
SMC ID:
1174/16
Indication:
As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy.
Pharmaceutical company
Boehringer Ingelheim Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
11 July 2016